Coherus Oncology, Inc. · NASDAQ:CHRS
Coherus Oncology — Investor Presentation (September 2026)
25 slides from Coherus Oncology's investor presentation, September 2026
Slide 1: Corporate Presentation
OVERCOMING IMMUNE RESISTANCE IN CANCER Corporate Presentation September 2026 ©2026 Coherus Oncology, Inc.
Slide 2: Disclaimers
Disclaimers Forward-Looking Statements Except for the historical information contained herein, the matters set forth in this presentation are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking stateme
Slide 3: Overcoming Immune Resistance in Cancer
COHERUS ONCOLOGY Overcoming Immune Resistance in Cancer • Our Vision and Corporate Summary • Overcoming Immune Resistance through Treg Depletion • Tagmokitug: Highly-Selective, Potentially Best-in- Class CCR8+ Treg Depleter • Casdozokitug: First-in-Class IL-27 Antagonist ©2026 Coherus Oncology, Inc.
Slide 4: Our Vision: Help People With Cancer Live Longer
Our Vision: Help People With Cancer Live Longer Developing Novel Agents Designed to Overcome Immune Resistance and Extend Survival Our ambition is to translate a deeper understanding of tumor immune resistance into medicines that deliver durable benefit for patients. DISCOVER DEVELOP DELIVER novel i
Slide 5: Coherus Oncology - Commercial Stage Innovative Oncology Company
Coherus Oncology - Commercial Stage Innovative Oncology Company Growing Revenues and Promising Pipeline Assets Progressing Through Development Tagmokitug Casdozokitug LOQTORZI® CCR8+ driven Treg Depleter IL-27 Antagonist Next generation PD-1 • High selectivity, potentially • First-in-Class anti IL-2
Slide 6: LOQTORZI Demonstrated Clinical Differentiation and Survival
LOQTORZI® Demonstrated Clinical Differentiation and Survival Only Preferred Regimen in NCCN NPC Guidelines Proven activity in 1L ESCC Clinically Meaningful and Preferred regimen established irrespective of PD-L1 status Practice Changing Survival in NCCN NPC guidelines Hazard Ratio PD-L1 ≥ 10 PD-L1 <
Slide 7: Commercial Execution Driving Revenue Growth
Commercial Execution Driving Revenue Growth Focused on Key Revenue Drivers Steady revenue growth, projected to Key Driver: Overcoming Keytruda and ~$150-200 million annualized in 2028 chemo-only regimens 6-year survival data 2026 2027 2028 64.8 months for LOQTORZI® + chemo vs 33.7 months for chemo a
Slide 8: Coherus Oncology Pipeline: Overcoming Immune Resistance in Cancer
Coherus Oncology Pipeline: Overcoming Immune Resistance in Cancer Differentiated Pipeline Progressing to Near Term Data Readouts UPCOMING PROGRAM TARGET INDICATION COMBINATION DEVELOPMENT STAGE READOUT Preclinical Phase 1 Phase 2 Phase 3 Marketed Gemcitabine / Next-Gen 1L NPC Cisplatin PD-1 Inhibito
Slide 9: Overcoming Immune Resistance in Cancer
COHERUS ONCOLOGY Overcoming Immune Resistance in Cancer • Vision and Corporate Summary • Overcoming Immune Resistance through Treg Depletion • Tagmokitug: Highly-Selective, Potentially Best- in-Class CCR8+ Treg Depleter • Casdozokitug: Potentially First-in-Class IL-27 Antagonist ©2026 Coherus Oncolo
Slide 10: Tregs Are Immunosuppressive T Cells Supporting Immune Homeostasis
Tregs Are Immunosuppressive T Cells Supporting Immune Homeostasis High Numbers of Tumor-Infiltrating Tregs are Predictive of Worse Clinical Outcomes Regulatory T cells (Tregs) suppress anti- Presence of Tregs is prognostic for lower tumor immune responses survival outcomes in several solid tumors •
Slide 11: Cytotoxic Therapies Expand and Activate Tregs
Cytotoxic Therapies Expand and Activate Tregs Potential Synergy With Treg Depletion to Improve Overall Survival PD-(L)1 Some anticancer Chemotherapy therapies increase Tregs in the TME, VEGF Upregulated which is associated KRAS CCR8+ Tregs with treatment Radiation resistance ADCs • Directly increase
Slide 12: CCR8 is Expressed on the Surface and Upregulated in Intratumoral Tregs
CCR8 is Expressed on the Surface and Upregulated in Intratumoral Tregs Depletion of CCR8 Tregs Preferentially Within the Tumor CCR8 is upregulated on intratumoral Depletion of CCR8+ Tregs through effector NK Cell activation Treg cells of many solid tumors induce antitumor responses Tumor cell Activa
Slide 13: Tumor Immune Regulatory Index (TIRI)
Tumor Immune Regulatory Index (TIRI) Defines Immune Context Associated with Potential Tagmokitug Clinical Benefit Implications for tagmokitug Precedent: CPS (PD-L1 level) Analogous approach: TIRI development • Broadly used for PD-1 therapy • The tumor-immune regulatory • Patient selection for future
Slide 14: Overcoming Immune Resistance in Cancer
COHERUS ONCOLOGY Overcoming Immune Resistance in Cancer • Vision and Corporate Summary • Overcoming Immune Resistance through Treg Depletion • Tagmokitug: Highly-Selective, Potentially Best-in-Class CCR8+ Treg Depleter • Casdozokitug: First-in-Class IL-27 Antagonist ©2026 Coherus Oncology, Inc. 14
Slide 15: Tagmokitug has Demonstrated Potentially Best-In-Class Properties
Tagmokitug has Demonstrated Potentially Best-In-Class Properties ADCC/ADCP-enhanced IgG1 Treg Depleter Advancing Differentiated with Ideal Pharmacological BMS High Selectivity Properties AbbVie ✓ Only known selective CCR8 mAb, ✓ High affinity (pM) and potency with Sino showing no off-target binding
Slide 16: Tumor Response in the Tagmokitug + Toripalimab Combination
Tumor Response in the Tagmokitug + Toripalimab Combination Proof of Concept of Immune Remodeling Restoring Antitumor Activity Tumor biopsy from HNSCC patients (tagmokitug Confirmed partial response in 4L PD-1 refractory monotherapy) demonstrate proof of mechanism patient with combination tagmokitug/
Slide 17: Tagmokitug Overarching Clinical Development Objectives
Tagmokitug Overarching Clinical Development Objectives Select Patients, Tumor Types and Lines of Therapy for Further Development Ongoing Tagmokitug Study Objectives / Clinical Studies Hypotheses Tested Overarching Objectives 2L Head and Neck Select tumor types for further development 2L Upper GI Ade
Slide 18: Tagmokitug in Head and Neck Squamous Cell Carcinoma
Tagmokitug in Head and Neck Squamous Cell Carcinoma Fully Enrolled – Initial Readout in October 2026 Ongoing Clinical Study Rationale Current Data Snapshot 2L Head and Neck cancer (HNSCC) • Immune remodeling and antitumor • Higher activity in HPV-positive activity previously demonstrated in patients
Slide 19: TREGCHECK Platform: Clinical Study Evaluating Tagmokitug With Combinations
TREGCHECK Platform: Clinical Study Evaluating Tagmokitug With Combinations Expand PD-1 Inhibitor Indications and Enhance the Activity of Cancer Drugs Other Than PD-1 Inhibitors Reverse PD-1 Resistance 2L Head and Neck Cancer 2L Gastric, Gastro-esophageal-junction 2L Esophageal Squamous Cell Carcinom
Slide 20: Overcoming Immune Resistance in Cancer
COHERUS ONCOLOGY Overcoming Immune Resistance in Cancer • Vision and Corporate Summary • Overcoming Immune Resistance through Treg Depletion • Tagmokitug: Highly-Selective, Potentially Best-in- Class CCR8+ Treg Depleter • Casdozokitug: First-in-Class IL-27 Antagonist ©2026 Coherus Oncology, Inc. Pro
Slide 21: Casdozokitug is a First-in-Class High Affinity IL-27 Antagonist
Casdozokitug is a First-in-Class High Affinity IL-27 Antagonist Designed to Overcome Immune Suppression by Blocking IL-27 in the TME IL-27 modulates immune response, immune pathology, and tumor immune evasion Casdozokitug blocks IL-27 and increases pro- inflammatory cytokines and NK cell activation,
Slide 22: Casdozokitug Combination Demonstrated Clinical Activity and Safety
Casdozokitug Combination Demonstrated Clinical Activity and Safety Phase 2 Study Final Results in 1L HCC: 11 Objective Responses, Including 5 CRs CADILYZE 201 Study: Casdozokitug + Atezo + Bev in 1L HCC Target Lesion Change Over Time (n=28) Best Overall Response RECIST v1.1 (n=29) 140 Patient Contin
Slide 23: Casdozokitug Ongoing CADILYZE 202 Phase 2 Study in 1L HCC
Casdozokitug Ongoing CADILYZE 202 Phase 2 Study in 1L HCC Fully Enrolled in March 2026 – Data Continues to Mature Current Study Rationale Current SoC / Market opportunity • IL-27 expression prevalent in • SOC: Atezolizumab + Arm A: barrier tissues (e.g., Lung, Liver) bevacizumab casdozo (Dose 1) + t
Slide 24: Coherus Oncology - Commercial Stage Innovative Oncology Company
Coherus Oncology - Commercial Stage Innovative Oncology Company Growing Revenues and Promising Pipeline Assets Progressing Through Development Tagmokitug Casdozokitug LOQTORZI® CCR8+ driven Treg Depleter IL-27 Antagonist Next generation PD-1 • High selectivity, potentially • First-in-Class anti IL-2
Slide 25: Corporate Presentation
OVERCOMING IMMUNE RESISTANCE IN CANCER Corporate Presentation September 2026 ©2026 Coherus Oncology, Inc.
Coherus Oncology — Investor Presentation (September 2026) on 6ix